Cellectar Biosciences expanded its global IP estate and announced oversubscribed financing of up to $140 million. The funding supports iopofosine I 131 regulatory filings and a confirmatory study in Waldenström macroglobulinemia.
ALX Oncology has multiple 2026 catalysts for Evorpacept and ALX2004. Interim ASPEN-09 data are expected in Q3 2026, while an initial safety update from the phase 1 ALX2004 trial is expected in 1H 2026.
CAR T-cell therapy demonstrates near-98% response rates in multiple myeloma trials, but only 2.6% of eligible patients receive treatment. Black patients face substantially lower access, with structural and institutional barriers limiting availability of the specialized therapy.
MajesTEC-9 trial demonstrates teclistamab's superiority over standard care in second-line multiple myeloma treatment, with significant progression-free survival and overall survival benefits supporting earlier use of the BCMA-targeting bispecific antibody.
The FDA has granted fast track designation to QRX003 for Netherton Syndrome and IBI3003 for relapsed or refractory multiple myeloma, while also accepting regulatory applications for other therapies addressing serious conditions with unmet medical needs.
The FDA approved Tecvayli plus Darzalex Faspro for relapsed or refractory multiple myeloma after at least one prior therapy, and accepted a new drug application for iberdomide plus daratumumab and dexamethasone with a PDUFA date of August 17, 2026.
Bristol Myers Squibb's growth portfolio increased 17% in 2025, partially offsetting a 15% decline in legacy products facing generic competition. The company's stock gained 11.4% in the past month on strong fourth-quarter results.
Bristol Myers Squibb and SystImmune reported that antibody-drug conjugate izalontamab brengitecan achieved statistically significant improvements in both progression-free and overall survival versus chemotherapy in a Phase III trial for triple-negative breast cancer.
Bristol Myers Squibb reported fourth quarter and full year 2025 results that beat consensus expectations, with total revenues of $48.3 billion. The company announced FDA acceptance of its new drug application for iberdomide and positive Phase 2 results for Reblozyl.
Novel CELMoD agents are being evaluated to address T-cell exhaustion in multiple myeloma patients, while CAR T-cell therapy CARVYKTI shows longer-term survival benefits. Nearly 200,000 people in the U.S. live with this blood cancer.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07369895 |
Clinical Study of O&D-001 Injection in the Treatment of Relapsed or Refractory Multiple Myeloma |
RECRUITING | PHASE1 |
| NCT07312188 |
A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma |
RECRUITING | PHASE2 |
| NCT07138209 |
A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma |
RECRUITING | PHASE3 |
| NCT07116616 |
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma |
RECRUITING | PHASE1/PHASE2 |
| NCT07018050 |
Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma |
RECRUITING | PHASE2 |
| NCT06825845 |
Long Term Follow-up Observational Study in Patients Treated with Gene-Modified T-Cell Therapy |
NOT_YET_RECRUITING | |
| NCT06604715 |
A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma |
RECRUITING | PHASE1 |
| NCT06574568 |
A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma |
RECRUITING | PHASE1 |
| NCT06500507 |
A Study of QLS4131 in Patients With Recurrent or Refractory Multiple Myeloma |
NOT_YET_RECRUITING | PHASE1 |
| NCT06425991 |
A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma |
ACTIVE_NOT_RECRUITING | PHASE1 |
